1-(2-溴苯基)丙烷-1-酮 | 62403-86-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-溴苯基)丙烷-1-酮
• 英文名称: 2-bromopropiophenone
• 英文别名: 1-(2-bromophenyl)propan-1-one；o-bromopropiophenone；2'-Bromopropiophenone
• CAS: 62403-86-5
• 化学式: C₉H₉BrO
• mdl: MFCD10698693
• 分子量: 213.074
• InChiKey: SFCCOHHWKRVDHH-UHFFFAOYSA-N

物化性质

• 沸点：
  125 °C
• 密度：
  1.386±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 储存条件：
  存储条件：2-8°C，密封，干燥

反应信息

• 作为反应物：
  描述：

  1-(2-溴苯基)丙烷-1-酮 在 盐酸 、 lithium hydroxide 、 叠氮磷酸二苯酯 、 水 、 四氯化钛 作用下， 以 乙醚 为溶剂， 生成 3-amino-4-(2-bromophenyl)-2,6-bis(methoxycarbonyl)-5-methylpyridine
  参考文献：
  名称：

  Inverse electron demand Diels-Alder reactions of heterocyclic azadienes. Studies on the total synthesis of lavendamycin: investigative studies on the preparation of the CDE .beta.-carboline ring system and AB quinoline-5,8-quinone ring system

  摘要：

  DOI：

  10.1021/jo00350a069
• 作为产物：
  描述：

  1-(2-氨基-苯基)-丙烷-1-酮 在 硫酸 、 copper(I) bromide 作用下， 生成 1-(2-溴苯基)丙烷-1-酮
  参考文献：
  名称：

  CXLIII.—简单烷基苯基酮的邻位和间位衍生物

  摘要：

  DOI：

  10.1039/jr9300001128

文献信息

• Preparation of preparing substituted indanones
  申请人：Basell Polypropylen GmbH

  公开号：US06492539B1

  公开（公告）日：2002-12-10

  a process for the preparation of indanones of the formula II from, indanones of the formula I or of indanones of the formula IIa from indanones of the formula Ia comprises reacting an indanone of the formula I or Ia with a coupling component.

  从公式I的茚酮或公式Ia的茚酮与偶联组分反应，制备公式II的茚酮或从公式Ia的茚酮制备公式IIa的茚酮的方法。
• Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation, Corporation of the State of Delaware

  公开号：US20030018025A1

  公开（公告）日：2003-01-23

  Disclosed are compounds of the formula: 1 wherein R 1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R 3 and R 4 are organic or inorganic substitutents which may togther form ring structutes; m is zero, one or two; and R 5 and R 6 are are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  揭示了以下式的化合物： 其中R1代表可选择地取代的芳基、杂环芳基、芳基烷基或环烷基基团；X、Z和Y为可选择地取代的氮或碳原子；R3和R4为有机或无机取代基，可能共同形成环结构；m为零、一或二；R5和R6为有机或无机取代基； 以及其药学上可接受的盐， 这些化合物是高度选择性的部分激动剂或拮抗剂，作用于脑多巴胺受体亚型或其前药，并可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。
• Heteroaryl compounds as P2Y1 receptor inhibitors
  申请人：Sutton C. James

  公开号：US20060173002A1

  公开（公告）日：2006-08-03

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新颖的杂环芳基化合物及其类似物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及调节P2Y1受体活性治疗对其敏感的疾病的方法。
• α,β-Functionalization of saturated ketones with anthranils via Cu-catalyzed sequential dehydrogenation/aza-Michael addition/annulation cascade reactions in one-pot
  作者：Dipak Kumar Tiwari、Mandalaparthi Phanindrudu、Sandip Balasaheb Wakade、Jagadeesh Babu Nanubolu、Dharmendra Kumar Tiwari

  DOI：10.1039/c7cc01195d

  日期：——

  An efficient method to access functionalized quinolines from the readily available saturated ketones and anthranils have been explored. This one-pot cascade reaction involves the in situ generation of α,β-unsaturated ketones by the copper catalysed dehydrogenation of saturated ketones followed by the aza-Michael addition of anthranils and subsequent annulation.

  已经研究了从容易获得的饱和酮和蒽基中获得官能化喹啉的有效方法。这种一锅法级联反应涉及通过铜催化饱和酮的脱氢反应，然后通过氮杂-迈克尔加成蒽基并随后进行环合反应，原位生成α，β-不饱和酮。
• Pyrrolo\x9b2,3-d!pyrimidines and their use
  申请人：Novartis Finance Corp.

  公开号：US05869485A1

  公开（公告）日：1999-02-09

  The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0, R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; and R.sub.1 and R.sub.2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R.sub.1 and R.sub.2 to be hydrogen, or R1 and R2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl; or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.

  本发明涉及在治疗肿瘤疾病和其他增殖性疾病（例如银屑病）中使用下面提及的化合物，以及该类新颖化合物。这些化合物是公式I的化合物：##STR1##，其中n为0到5，当n不为0时，R为选自卤素、烷基、三氟甲基和烷氧基的一个或多个取代基；R.sub.1和R.sub.2各自独立地为烷基，或为未取代或被卤素、三氟甲基、烷基或烷氧基取代的苯基，两个自由基R.sub.1和R.sub.2中的一个也可以是氢，或者R1和R2共同形成一个有2到5个碳原子的未取代或被烷基取代的亚烷基链；或其盐。公式I的化合物可以抑制蛋白激酶，例如表皮生长因子（EGF）受体的酪氨酸蛋白激酶。